Joel E. Gallant

31.9k citations
202 papers · 26.3k · 15 hit papers · h-index 65

Impact in

  • Virology top 0.05%
    • HIV Research and Treatment
    • HIV/AIDS Research and Interventions
    • HIV/AIDS drug development and treatment
    • Antifungal resistance and susceptibility

Papers in

    • HIV/AIDS drug development and treatment 108
    • HIV/AIDS Research and Interventions 51
    • Antifungal resistance and susceptibility 4
    • HIV Research and Treatment 25

Joel E. Gallant

197 papers receiving 25.1k citations

Joel E. Gallant's Hit Papers

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial 2017 · 314 citations
3140+11+22Years since publication1k2k3k4k5k

Peers

Joel E. Gallant
Comparison fields: 5 of 162
  • Virology 5.9k
  • Infectious Diseases 15.8k
  • Emergency Medicine 2k
  • Epidemiology 1.9k
  • Family Practice 131
Replace Paul A. Volberding with:
Paul A. Volberding United States
José M. Gatell Spain
Margaret A. Fischl United States
Bruno Ledergerber Switzerland
Michael John Gill Canada
Diane V. Havlir United States
Scott M. Hammer United States
Matthias L. Cavassini Switzerland
Diana M. Gibb United Kingdom
Martin Hirsch United States
Joel E. Gallant relative to Paul A. Volberding United States Paul A. Volberding's profile →
Citations per field
00.5×2×3.1×
Paul A. Volberding · 1×
Citations per year

Countries citing papers authored by Joel E. Gallant

Since Specialization
Citations

This map shows the geographic impact of Joel E. Gallant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel E. Gallant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel E. Gallant more than expected).

Fields of papers citing papers by Joel E. Gallant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel E. Gallant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel E. Gallant. The network helps show where Joel E. Gallant may publish in the future.

Co-authors

The 25 scholars most cited alongside Joel E. Gallant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joel E. Gallant Line = papers co-authored together Joel E. Gallant links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 202 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Hit paper breakdown →
20115709
2
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
Hit paper breakdown →
19972637
3
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
Hit paper breakdown →
19991793
4
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
Hit paper breakdown →
20161324
5
Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients A 3-Year Randomized Trial
Hit paper breakdown →
20041191
6
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Hit paper breakdown →
2006763
7
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Hit paper breakdown →
2016563
8
Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine
Hit paper breakdown →
1992470
9
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
Hit paper breakdown →
2014411
10
Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Hit paper breakdown →
2013406
11
Antiretroviral Treatment of Adult HIV Infection
Hit paper breakdown →
2014403
12
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Hit paper breakdown →
2012398
13
Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Hit paper breakdown →
2009397
14 2003395
15 2006365
16
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Hit paper breakdown →
2017314
17 2014299
18 2005255
19
Medical Management of HIV Infection
1996226
20 2013224

About Joel E. Gallant

Joel E. Gallant is a scholar working on Infectious Diseases, Virology, Emergency Medicine, Epidemiology and Hepatology, having authored 202 papers that have together received 26.3k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (108 papers), HIV/AIDS Research and Interventions (51 papers), HIV Research and Treatment (25 papers), HIV-related health complications and treatments (18 papers), Pneumocystis jirovecii pneumonia detection and treatment (9 papers), Viral-associated cancers and disorders (5 papers), Antifungal resistance and susceptibility (4 papers) and Hepatitis C virus research (4 papers). The work is most often cited by research in Virology (5.9k citations), Infectious Diseases (15.8k citations), Emergency Medicine (2k citations), Epidemiology (1.9k citations) and Family Practice (131 citations). Joel E. Gallant has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Richard E. Chaisson, Robert F. Siliciano, Richard D. Moore, Thomas C. Quinn, Diana Finzi, Theodore C. Pierson, Karen R. Chadwick, Jeanne C. Keruly, Andrew Cheng and Joseph B. Margolick. Their work appears in journals such as Clinical Infectious Diseases, AIDS, JAIDS Journal of Acquired Immune Deficiency Syndromes, The Journal of Infectious Diseases and Open Forum Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact